Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's disease

Annals of General Psychiatry

Volumn 9, Issue , 2010, Pages

  Furuse, Tsutomu ^a   Hashimoto, Kenji ^b  

^a ASAHIKAWA RED CROSS HOSPITAL   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; FLUVOXAMINE; OLANZAPINE;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN INFARCTION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DELIRIUM; DELIRIUM RATING SCALE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE INCREASE; FEMALE; GASTROINTESTINAL SYMPTOM; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LUNG CONGESTION; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; RATING SCALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER; VISUAL HALLUCINATION;

EID: 76749153376     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-9-6     Document Type: Article

References (18)

1. Fong TG, Tulebaev SR, Inouye SK. Delirium in elderly adults: diagnosis, prevention and treatment. Nat Rev Neurol. 2009, 5(4):210-220. 10.1038/nrneurol.2009.24, 19347026.
2. Hashimoto K, Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des 2006, 12:3857-3876. 10.2174/138161206778559614, 17073684.
3. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell 2007, 131:596-610. 10.1016/j.cell.2007.08.036, 17981125.
4. Hashimoto K. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent Nerv Syst Agents Med Chem. 2009, 9(3):197-204.
5. Hayashi T, Stahl SM. The sigma-1 receptor and its role in the treatment of mood disorders. Drugs Future 2009, 34:137-146.
6. Ishikawa M, Hashimoto K. The role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases. J Receptor Ligand Channel Res 2009, 2010:3.
7. Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, Oda K, Miyatake R, Fujisaki M, Shimizu E, Shirayama Y, Iyo M, Hashimoto K. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biol Psychiatry 2007, 62:878-883. 10.1016/j.biopsych.2007.04.001, 17662961.
8. Trzepacz PT, Baker RW, Greenhouse J. A symptom rating scale for delirium. Psychiatry Res 1988, 23:89-97. 10.1016/0165-1781(88)90037-6, 3363018.
9. Cockrell JR, Folstein MF. Mini-Mental State Examination (MMSE). Psychopharmacol Bull 1988, 24:689-692.
10. Roth A, Akyol S, Nelson JC. Delirium associated with the combination of a neuroleptic, an SSRI, and benztropine. J Clin Psychiatry 1994, 55:492-495.
11. Amir I, Dano M, Joffe A. Recurrent toxic delirium in a patient treated with SSRIs: is old age a risk factor?. Isr J Psychiatry Relat Sci 1997, 34:119-121.
12. Byerly MJ, Christensen RC, Evans D. Delirium associated with a combination of sertraline, haloperidol, and benztropine. Am J Psychiatry 1996, 153:965-966.
13. Armstrong SC, Schweitzer SM. Delirium associated with paroxetine and benztropine combination. Am J Psychiatry 1997, 154:581-582.
14. Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology 2007, 32:514-521. 10.1038/sj.npp.1301047, 16495935.
15. Nishimura T, Ishima T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS ONE 2008, 3:e2558. 10.1371/journal.pone.0002558, 2435603, 18596927.
16. Ishima T, Fujita Y, Kohno M, Kunitachi S, Horio M, Takatsu M, Minase T, Tanibuchi Y, Hagiwara H, Iyo M, Hashimoto K. Improvement of phencyclidine-induced cognitive deficits in mice by subsequent subchronic administration of fluvoxamine, but not sertraline. Open Clin Chem J 2009, 2:7-11. 10.2174/1874241600902010007.
17. Weber JB, Coverdale JH, Kunik ME. Delirium: current trends in prevention and treatment. Intern Med J 2004, 34:115-121. 10.1111/j.1444-0903.2004.00549.x, 15030459.
18. Schneider LS, Dagernab KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia. Meta-analysis of randomized placebo-controlled trials. JAMA 2005, 294:1934-1943. 10.1001/jama.294.15.1934, 16234500.